Quercetin Side Effects

Reported Quercetin side effects

Quercetin has a favorable safety profile at typical supplementation doses with few serious adverse events reported in clinical trials up to 1500 mg daily for 12 weeks and extended use at 500-1000 mg daily. Dietary intake through food is universally safe. Gastrointestinal tolerance is generally good. Reported effects include mild nausea, gastric discomfort, loose stools, and bloating at doses above 1000 mg daily, typically mitigated by taking with food or dividing into multiple daily doses. Rare reports of more severe gastrointestinal symptoms occur with quercetin aglycone at very high doses (2000+ mg daily). Headache: mild transient headache has been reported at initiation of high-dose supplementation, usually resolving within 2-3 days. Paresthesia and peripheral tingling: rare reports at doses above 1000 mg daily; mechanism unclear, reversible on dose reduction. Renal concerns: a single case report (Choi 2000) of acute renal injury with intravenous quercetin at 1700 mg/m² in a cancer patient study. Oral quercetin at typical supplementation doses has not been associated with renal dysfunction. High-dose oral quercetin should be used cautiously in patients with pre-existing renal impairment, though no clear dose-limiting renal signal exists. Drug interactions — clinically significant and warranting attention: Cyclosporine: quercetin increases cyclosporine levels through CYP3A4 and P-glycoprotein inhibition. Clinically significant interaction; patients on cyclosporine should avoid quercetin supplementation or require dose adjustment under specialist supervision. Warfarin and anticoagulants: quercetin has weak antiplatelet and anticoagulant activity and modest CYP2C9 inhibition. Warfarin patients should monitor INR carefully if adding quercetin; the interaction is usually mild but can accumulate. Digoxin: quercetin inhibits P-glycoprotein which may increase digoxin absorption. Monitor digoxin levels if adding quercetin. Fluoroquinolones: quercetin may antagonize fluoroquinolone antibacterial activity by binding DNA gyrase at the same site. Separate doses by 2-4 hours or avoid during active fluoroquinolone therapy. Some statins: quercetin modestly inhibits CYP3A4 and OATP1B1, which may increase exposure to simvastatin, atorvastatin, and lovastatin. Clinically meaningful interaction is uncommon at typical doses but possible at high doses. Chemotherapy agents: quercetin's P-glycoprotein and CYP3A4 effects may interact with chemotherapy agents that are P-gp or CYP3A4 substrates (paclitaxel, doxorubicin, etoposide, vinca alkaloids, tamoxifen). Oncology patients should discuss supplementation with their oncologist before adding quercetin. Tyrosine kinase inhibitors (dasatinib, imatinib, gefitinib, erlotinib): quercetin has its own tyrosine kinase inhibition; the senolytic D+Q combination is an intentional synergy but in other oncologic contexts the combination may have unintended effects. Specialist oversight required. Antihypertensive medications: quercetin's modest blood-pressure-lowering effect may be additive with prescribed antihypertensives. Monitor blood pressure and adjust as needed. Pregnancy: human safety data at supplementation doses are limited. Dietary intake through food is unambiguously safe and encouraged. High-dose supplementation during pregnancy is generally avoided in the absence of specific medical indication. Lactation: limited data. Dietary intake is safe. Supplementation at typical doses is considered low-risk but not well-studied. Pediatric use: not routinely indicated for healthy children. Dietary intake is beneficial. Specific medical indications (pediatric allergic rhinitis, chronic urticaria) may warrant supplementation under pediatric or allergy specialist guidance. Liver function: generally not adversely affected. Case reports of hepatitis associated with quercetin-containing supplements have typically involved complex formulations with other ingredients and unclear causal attribution. Thyroid function: quercetin can inhibit thyroid peroxidase and sodium-iodide symporter at high concentrations in vitro. Clinical thyroid dysfunction from quercetin supplementation has not been reported. Patients with Hashimoto thyroiditis or pre-existing thyroid disease should discuss supplementation with their endocrinologist. Iron absorption: quercetin chelates iron and can modestly reduce dietary non-heme iron absorption when taken at the same meal. Patients with iron deficiency anemia should separate iron supplementation from quercetin dosing by 2-4 hours. Hormone-sensitive conditions: quercetin has weak phytoestrogenic activity. Theoretical concerns in estrogen-sensitive cancers have been raised but epidemiologic data do not support harm; practical guidance is to maintain dietary intake through food and use supplementation only with specialist guidance in active estrogen-sensitive cancer contexts. Surgery: the antiplatelet effect may warrant discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Discuss with surgical team. Extremely high-dose research protocols (2000+ mg daily): most safety data are from short-term trials; long-term safety at doses above 1500 mg daily is less well-characterized. Conservative practice is to use moderate doses (500-1000 mg daily) for maintenance and reserve higher doses for specific short-term indications. Allergy: quercetin itself is not a common allergen. Supplement excipients (gelatin capsules, vegetable fillers) may cause reactions in sensitive individuals. Natural source materials (onions, apples) can cause allergies in those with pre-existing oral allergy syndromes. Overall, quercetin supplementation at doses of 500-1500 mg daily in most adults for typical indications is well-tolerated. The main practical considerations are: (1) drug interactions with cyclosporine, warfarin, some statins, and certain chemotherapy agents; (2) surgical bleeding risk; (3) iron absorption competition with concurrent iron supplementation; and (4) limited pregnancy data suggesting caution with high-dose supplementation. The risk-benefit profile is favorable for most adult users with appropriate clinical context.

When to continue, reduce, or stop Quercetin

Quercetin contraindications

Contraindications for quercetin supplementation are generally relative rather than absolute, with the most clinically important being specific drug interactions. Absolute contraindications: None in typical adults at standard supplementation doses. Quercetin has an exceptionally favorable safety profile across multiple large studies. Relative contraindications and caution situations: Cyclosporine therapy — quercetin substantially increases cyclosporine exposure through CYP3A4 and P-glycoprotein inhibition. Avoid quercetin supplementation in solid organ transplant recipients or other cyclosporine users without specialist supervision. Warfarin anticoagulation — quercetin has modest antiplatelet activity and weak CYP2C9 inhibition. Monitor INR at 1-2 weeks after starting or stopping quercetin. Often does not require warfarin dose adjustment but occasional clinically meaningful interactions occur. Digoxin — quercetin inhibits P-glycoprotein, potentially increasing digoxin absorption. Monitor digoxin levels when adding quercetin. Tyrosine kinase inhibitor chemotherapy (dasatinib, imatinib, erlotinib, gefitinib, sunitinib) — quercetin has its own tyrosine kinase inhibition which may improve or alter the therapeutic or toxic effects. The D+Q senolytic combination is an intentional synergy requiring specialist supervision. Outside of intentional senolytic use, oncology patients should discuss supplementation with their oncologist. Fluoroquinolone antibiotics — quercetin binds to DNA gyrase at the same binding site as fluoroquinolones, potentially antagonizing antibacterial activity. Separate doses by 2-4 hours or suspend quercetin during active fluoroquinolone therapy. Some chemotherapy agents (paclitaxel, doxorubicin, vinca alkaloids) — CYP3A4 and P-gp substrates may have altered exposure. Discuss with oncologist. Some statins (simvastatin, atorvastatin, lovastatin) — CYP3A4 and OATP1B1 effects may increase statin exposure. Clinically meaningful interaction is uncommon at typical doses but possible at high quercetin doses. Antihypertensive medications — quercetin's modest blood pressure lowering effect may be additive. Monitor BP and adjust as needed. Antiplatelet medications (aspirin, clopidogrel, prasugrel) — additive bleeding risk. Usually not clinically significant at standard doses but monitor if both are prescribed. Iron supplementation — chelation reduces iron absorption. Separate by 2-4 hours if both are being actively supplemented. Pregnancy — dietary intake through food is unambiguously safe. Supplementation at typical doses (500-1000 mg daily) during pregnancy has limited safety data. Conservative practice is to rely on dietary intake and avoid high-dose supplementation during pregnancy without specific medical indication. Lactation — limited data at supplementation doses. Dietary intake is safe. Standard supplementation doses considered low-risk. Pediatric use — not routinely indicated. Dietary intake through food is beneficial. Specific pediatric indications (chronic urticaria, allergic rhinitis) may warrant supplementation under allergist or pediatric specialist supervision. Renal impairment — one case report of acute renal injury with IV quercetin at 1700 mg/m² has raised theoretical caution at very high doses. Oral quercetin at typical supplementation doses has not shown renal toxicity. Patients with pre-existing severe renal impairment should use moderate doses with clinical monitoring. Hepatic impairment — no specific hepatotoxicity identified. Conjugation is reduced in severe liver disease potentially altering pharmacokinetics. Monitor clinical response. Thyroid disease — quercetin inhibits thyroid peroxidase at high in vitro concentrations. No clinical thyroid dysfunction from supplementation has been reported. Patients with autoimmune thyroid disease can use typical doses but should discuss with endocrinologist if symptomatic changes occur. Hormone-sensitive cancers — quercetin has weak phytoestrogenic activity. Theoretical caution exists in active estrogen-sensitive cancers. Dietary intake is acceptable; specialist consultation warranted before high-dose supplementation. Surgical planning — the antiplatelet effect warrants discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Severe or uncontrolled hypertension — quercetin's blood pressure lowering effect is modest but can be additive with antihypertensive therapy. Monitor carefully; do not rely on quercetin for uncontrolled hypertension requiring prescription management. Known allergy to quercetin source material — patients with oral allergy syndrome to apples, onions, or other quercetin-rich foods may have reactions to natural-source-derived quercetin supplements. Synthetic quercetin or different-source extracts may be alternatives. Gout — theoretical benefit through xanthine oxidase inhibition; no established dosing protocol for gout but some patients use as adjunctive therapy. IV quercetin — avoid outside of research contexts. Oral is the established route. Extreme doses (2000+ mg daily) for prolonged periods — long-term safety less characterized than standard dosing ranges. Use moderate doses (500-1000 mg daily) for maintenance; reserve higher doses for short-term specific indications. Children with allergic conditions — pediatric use of quercetin for allergic rhinitis has limited data; pediatric-specific dosing and safety assessment should be guided by allergy or pediatric specialist. Overall, quercetin supplementation at doses of 500-1000 mg daily in most adults has a favorable risk-benefit profile. The main practical considerations are drug interactions (cyclosporine, warfarin, fluoroquinolones, tyrosine kinase inhibitors), surgical bleeding risk, iron absorption competition, and the need for bioavailability-enhanced forms to reach therapeutic plasma concentrations. The D+Q senolytic combination is a specialist supervision protocol and should not be self-administered.

Why vendor quality drives Quercetin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Quercetin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .